Phase II study of paclitaxel (Genaxol®) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC)

Chih Hung Chen, Wen Cheng Chang, Meng Chin Lin, Jen Wen Hsu, Tsu Yi Chao, Thomas C Y Tsao

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To assess the efficacy of 3-h paclitaxel infusion (Genaxol®) combined with cisplatin as the first line chemotherapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC). The aim of the present study is to evaluate the efficacy, safety, and quality of life of the combination of paclitaxel (Genaxol®) and cisplatin on Chinese patients. Methods: Forty-five patients with histology confirmed NSCLC, who met the selection criteria were enrolled in this study between June 1999 and May 2000. They were all at an advanced stage, i.e. stage IIIB with pleural effusion, or stage IV. Paclitaxel (Genaxol®) at a dose of 175 mg/m2 and cisplatin at a dose of 75 mg/m2 were administered every 3 weeks. Results: Of the 45 eligible patients, one had a CR and 19 achieved a PR. The overall response was 44.4% (95% CI: 29.3-59.5%). Eleven (24.4%) patients were in stable disease. The median time to disease progression for all patients was 5.5 months (95% CI: 4.0-7.0 months). The median survival was 11.1 months (95% CI: 6.6-15.6 months), the 1-year survival probability was 46.5%. Major non-hematology toxicities were asthenia, paresthesias, nausea, and vomiting. Hematological toxicity results showed 18 (40%) patients experienced grade 3/4 neutropenia but there was no febrile neutropenia, three (6.6%) patients experienced Grade 3 anemia, and one (2.2%) patient experienced Grade 3 thrombocytopenia. Conclusions: The combined paclitaxel and cisplatin regimen is safe and effective in the treatment of NSCLC but the quality of life is disappointed.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalLung Cancer
Volume38
Issue number1
DOIs
Publication statusPublished - Oct 1 2002
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Paclitaxel
Cisplatin
Quality of Life
TP protocol
Asthenia
Febrile Neutropenia
Survival
Paresthesia
Pleural Effusion
Neutropenia
Nausea
Patient Selection
Vomiting
Disease Progression
Anemia
Histology
Safety
Drug Therapy

Keywords

  • Chemotherapy
  • Cisplatin
  • Non-small cell lung cancer
  • Paclitaxel
  • Response

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II study of paclitaxel (Genaxol®) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC). / Chen, Chih Hung; Chang, Wen Cheng; Lin, Meng Chin; Hsu, Jen Wen; Chao, Tsu Yi; Tsao, Thomas C Y.

In: Lung Cancer, Vol. 38, No. 1, 01.10.2002, p. 91-96.

Research output: Contribution to journalArticle

Chen, Chih Hung ; Chang, Wen Cheng ; Lin, Meng Chin ; Hsu, Jen Wen ; Chao, Tsu Yi ; Tsao, Thomas C Y. / Phase II study of paclitaxel (Genaxol®) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC). In: Lung Cancer. 2002 ; Vol. 38, No. 1. pp. 91-96.
@article{e594f46bc76245ab833287a5041075f0,
title = "Phase II study of paclitaxel (Genaxol{\circledR}) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC)",
abstract = "Purpose: To assess the efficacy of 3-h paclitaxel infusion (Genaxol{\circledR}) combined with cisplatin as the first line chemotherapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC). The aim of the present study is to evaluate the efficacy, safety, and quality of life of the combination of paclitaxel (Genaxol{\circledR}) and cisplatin on Chinese patients. Methods: Forty-five patients with histology confirmed NSCLC, who met the selection criteria were enrolled in this study between June 1999 and May 2000. They were all at an advanced stage, i.e. stage IIIB with pleural effusion, or stage IV. Paclitaxel (Genaxol{\circledR}) at a dose of 175 mg/m2 and cisplatin at a dose of 75 mg/m2 were administered every 3 weeks. Results: Of the 45 eligible patients, one had a CR and 19 achieved a PR. The overall response was 44.4{\%} (95{\%} CI: 29.3-59.5{\%}). Eleven (24.4{\%}) patients were in stable disease. The median time to disease progression for all patients was 5.5 months (95{\%} CI: 4.0-7.0 months). The median survival was 11.1 months (95{\%} CI: 6.6-15.6 months), the 1-year survival probability was 46.5{\%}. Major non-hematology toxicities were asthenia, paresthesias, nausea, and vomiting. Hematological toxicity results showed 18 (40{\%}) patients experienced grade 3/4 neutropenia but there was no febrile neutropenia, three (6.6{\%}) patients experienced Grade 3 anemia, and one (2.2{\%}) patient experienced Grade 3 thrombocytopenia. Conclusions: The combined paclitaxel and cisplatin regimen is safe and effective in the treatment of NSCLC but the quality of life is disappointed.",
keywords = "Chemotherapy, Cisplatin, Non-small cell lung cancer, Paclitaxel, Response",
author = "Chen, {Chih Hung} and Chang, {Wen Cheng} and Lin, {Meng Chin} and Hsu, {Jen Wen} and Chao, {Tsu Yi} and Tsao, {Thomas C Y}",
year = "2002",
month = "10",
day = "1",
doi = "10.1016/S0169-5002(02)00148-4",
language = "English",
volume = "38",
pages = "91--96",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Phase II study of paclitaxel (Genaxol®) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC)

AU - Chen, Chih Hung

AU - Chang, Wen Cheng

AU - Lin, Meng Chin

AU - Hsu, Jen Wen

AU - Chao, Tsu Yi

AU - Tsao, Thomas C Y

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Purpose: To assess the efficacy of 3-h paclitaxel infusion (Genaxol®) combined with cisplatin as the first line chemotherapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC). The aim of the present study is to evaluate the efficacy, safety, and quality of life of the combination of paclitaxel (Genaxol®) and cisplatin on Chinese patients. Methods: Forty-five patients with histology confirmed NSCLC, who met the selection criteria were enrolled in this study between June 1999 and May 2000. They were all at an advanced stage, i.e. stage IIIB with pleural effusion, or stage IV. Paclitaxel (Genaxol®) at a dose of 175 mg/m2 and cisplatin at a dose of 75 mg/m2 were administered every 3 weeks. Results: Of the 45 eligible patients, one had a CR and 19 achieved a PR. The overall response was 44.4% (95% CI: 29.3-59.5%). Eleven (24.4%) patients were in stable disease. The median time to disease progression for all patients was 5.5 months (95% CI: 4.0-7.0 months). The median survival was 11.1 months (95% CI: 6.6-15.6 months), the 1-year survival probability was 46.5%. Major non-hematology toxicities were asthenia, paresthesias, nausea, and vomiting. Hematological toxicity results showed 18 (40%) patients experienced grade 3/4 neutropenia but there was no febrile neutropenia, three (6.6%) patients experienced Grade 3 anemia, and one (2.2%) patient experienced Grade 3 thrombocytopenia. Conclusions: The combined paclitaxel and cisplatin regimen is safe and effective in the treatment of NSCLC but the quality of life is disappointed.

AB - Purpose: To assess the efficacy of 3-h paclitaxel infusion (Genaxol®) combined with cisplatin as the first line chemotherapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC). The aim of the present study is to evaluate the efficacy, safety, and quality of life of the combination of paclitaxel (Genaxol®) and cisplatin on Chinese patients. Methods: Forty-five patients with histology confirmed NSCLC, who met the selection criteria were enrolled in this study between June 1999 and May 2000. They were all at an advanced stage, i.e. stage IIIB with pleural effusion, or stage IV. Paclitaxel (Genaxol®) at a dose of 175 mg/m2 and cisplatin at a dose of 75 mg/m2 were administered every 3 weeks. Results: Of the 45 eligible patients, one had a CR and 19 achieved a PR. The overall response was 44.4% (95% CI: 29.3-59.5%). Eleven (24.4%) patients were in stable disease. The median time to disease progression for all patients was 5.5 months (95% CI: 4.0-7.0 months). The median survival was 11.1 months (95% CI: 6.6-15.6 months), the 1-year survival probability was 46.5%. Major non-hematology toxicities were asthenia, paresthesias, nausea, and vomiting. Hematological toxicity results showed 18 (40%) patients experienced grade 3/4 neutropenia but there was no febrile neutropenia, three (6.6%) patients experienced Grade 3 anemia, and one (2.2%) patient experienced Grade 3 thrombocytopenia. Conclusions: The combined paclitaxel and cisplatin regimen is safe and effective in the treatment of NSCLC but the quality of life is disappointed.

KW - Chemotherapy

KW - Cisplatin

KW - Non-small cell lung cancer

KW - Paclitaxel

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=0036805528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036805528&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00148-4

DO - 10.1016/S0169-5002(02)00148-4

M3 - Article

VL - 38

SP - 91

EP - 96

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -